In recent years, the clinical research on dementia has made dramatic progress owing to the practical application of biomarker diagnostic techniques, such as amyloid PET. The development of methods to predict or prevent disease onset by means of lifestyle changes and drugs are now considered. This project has been started on time. Our center performs the best data accumulation in Japan through clinical–imaging–pathological cooperation, and we will continue to accumulate data and resources covering hospital and local cohorts. Based on these datasets, our team aims to develop innovative AI-based dementia diagnosis, treatment, and care support technologies. The development and spread of the AI diagnosis system could lead to the realization of high-accuracy and low-cost diagnosis and treatment, bridging the gap of regional medical disparities and realization of tailor-made/individualized dementia prevention programs in the near future. As this program could accelerate the realization of a future society without dementia, we will promote the research in collaboration with researchers and healthcare professionals inside and outside the country.
Kenji Ishii, M.D.
Vice Director of Integrated Research Initiative for Living Well with Dementia
The AI Diagnosis System Team aims to develop and disseminate innovative technologies focusing on imaging diagnosis but deals with a wide range of technologies from the diagnosis to the treatment, nursing care, and prevention. Our center has a large number of imaging and clinical datasets. Their background pathology has been confirmed using autopsy or PET/fluid biomarkers, which are indispensable for the development of AI imaging diagnosis tools. We will work on the development of innovative AI diagnosis/intervention methods applicable from the preclinical to advanced stage of dementia.
